The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: A comprehensive review

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 2, 2012, Pages 176-183

  Zeichner, Simon ^a   Mihos, Christos G ^b   Santana, Orlando ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cancer; HMG CoA reductase; malignancies; pleiotropic effects; statins

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; BENDAMUSTINE; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUINDOSTATIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INULIN; IRINOTECAN; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRAVASTATIN; RITUXIMAB; ROSUVASTATIN; SIMVASTATIN; SORAFENIB; SULINDAC;

ARTIFICIAL EMBOLISM; BLADDER CANCER; BRAIN STEM TUMOR; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CASE CONTROL STUDY; CHILDHOOD CANCER; COLON ADENOMA; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EVENT FREE SURVIVAL; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEOPLASM; PANCREAS CANCER; PLEIOTROPY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; RISK REDUCTION; SKIN CANCER; STOMACH CANCER; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864696245     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.98967     Document Type: Review

References (101)

1. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomized trials. BMJ 2000;321:983-5.
2. Tonkin A, Aylward P, Colquhoun D, Glasziou P, Harris P, Huntet D, et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998;339: 1349-57.
3. Mihos CG, Santana O. Pleiotropic effects of the HMG-CoA reductase inhibitors. Int J Gen Med 2011;4:261-71.
4. Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxymethyl- glutaryl-CoA reductase inhibitors in cardiovascular disease: A comprehensive review. Cardiol Rev 2010;18:298-304.
5. Mihos CG, Artola RT, Santana O. The pleiotropic effects of the hydroxymethyl- glutaryl-CoA reductase inhibitors in rheumatologic disorders: A comprehensive review. Rheumatol Int 2012;32:287-94.
6. Endres M. Statins and stroke. J Cereb Blood Flow Metab 2005;25: 1093-110.
7. Liao JK. Beyond lipid lowering: The role of statins in vascular protection. Int J Cardiol 2002;86:5-18.
8. Li J, Li JJ, He JG, Nan JL, Guo YL, Xiong CM. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappa B pathway. Cardiovasc Ther 2010;28:8-14.
9. Tandon V, Bano G, Khajuria V, Parihar A, Gupta S. Pleiotropic effects of statins. Indian J Pharmacol 2005;37:77-85.
10. Li YC, Park MJ, Ye SK, Kim CW, Kim YN. Elevated levels of cholesterolrich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 2006;168: 1107-18.
11. Dulak J, Józkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: Relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005;5:579-94.
12. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, et al. Statin use and breast cancer: Prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006;98:700-7.
13. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 2008;17:1028-33.
14. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early breast cancer survivors. Breast Cancer Res Treat 2008;109:573-9.
15. Eaton M, Eklof J, Beal JR, Sahmoun AE. Statins and breast cancer in postmenopausal women without hormone therapy. Anticancer Res 2009;29:5143-8.
16. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut 2010;59:1572-85.
17. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: A meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007 10;25:3462-8.
18. Siddiqui AA, Nazario H, Mahgoub A, Pandove S, Cipher D, Spechler SJ. The long term use of statins is associated with a decrease incidence of adenomatous colon polyps. Digestion 2009;79:17-22.
19. Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG. Statin use and colorectal adenoma risk: Results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 2010;3:588-96.
20. Eddi R, Karki A, Shah A, DeBari VA, DePasquale JR. Association of type 2 diabetes and colon adenomas. J Gastrointest Cancer. 2012;43(1): 87-92.
21. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cell. Clin Cancer Res 1999;5:2223-9.
22. Lee J, Lee I, Han B, Park JO, Jang J, Park C. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 2011;103:674-88.
23. Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 2008;72:476-84.
24. Guruswamy S, Rao CV. Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention. Int J Oncol 2009;35:1037-43.
25. Tan N, Klein EA, Li J, Moussa AS, Jones JS. Statin use and risk of prostate cancer in a population of men who underwent biopsy. J Urol 2011;186:86-90.
26. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010;28:2653-9.
27. Bañez LL, Klink JC, Jayachandran J, Lark AL, Gerber L, Hamilton RJ, et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2010;19:722-8.
28. Hwang KE, Na KS, Park DS, Choi KH, Kim BR, Shim H, et al. Apoptotic induction by simvastatin in human lung cancer A549 cell via Akt signaling dependent down-regulation of surviving. Invest New Drugs 2010;29:945-52.
29. Graf H, Jüngst C, Straub G, Dogan S, Hoffmann RT, Jakobs T, et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 2008;78:34-8.
30. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886-91.
31. El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009;136:1601-8.
32. Fortuny J, de Sanjosé S, Becker N, Maynadié M, Cocco PL, Staines A, et al. Statin use and risk of lymphoid neoplasms: Results from the European Case-control study EPILYMPH. Cancer Epidemiol Biomarkers Prev 2006;15:921-5.
33. Nowakowski GS, Maurer MJ, Habermann TM, Ansell SM, Macon WR, Ristow KM, et al. Statin use and prognosis in patients with diffuse larger B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010;28:412-7.
34. Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D. Risk of multiple myeloma following medication use and medical conditions: A case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 2006;15:2342-7.
35. Schmidmaier R, Baumann P, Bumeder I, Meinhardt G, Straka C, Emmerich B. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 2007;79:240-3.
36. Khurana V, Sheth A, Caldito G, Barkin JS. Statins reduce the risk of pancreatic cancer in human: A case-control study of a half a million veterans. Pancreas 2007;34:260-5.
37. Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T, et al. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer 2007;43:2580-9.
38. Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in human: A case control study of 500,000 veterans. Urology 2008;71:118-22.
39. López-Aguilar E, Sepülveda-Vildósola AC, Betanzos-Cabrera Y, Rocha-Moreno YG, Gascón-Lastiri G, Rivera-Márquez H, et al. Phase II study of metronomic chemotherapy with thalidomide, carboplatinvincristine- fluvastatin in the treatment of brain stem tumors in children. Arch Med Res 2008;39:665-2.
40. Kusama T, Mukai M, Tatsuta M, Nakamura H, Inoue M. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylation of Rho. Int J Oncol 2006;29:217-23.
41. Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier JP, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study. Carcinogenesis 2001;22:1139-48.
42. Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Ghosh Choudhury G. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal 2010;22:749-55.
43. Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res 2008;10:R79.
44. Muck AO, Seeger H, Wallwiener D. Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 2004;42:695-700.
45. Sánchez CA, Rodríguez E, Varela E, Zapata E, Páez A, Massó FA, et al. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest 2008;26: 698-707.
46. Farina HG, Bublik DR, Alonso DF, Gomez DE. Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis 2002;19:551-9.
47. Kozar K, Kaminski R, Legat M, Kopec M, Nowis D, Skierski JS, et al. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 2004;24:1149-57.
48. Budman DR, Tai J, Calabro A. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Breast Cancer Res Treat 2007;104:93-101.
49. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;1;23:8606-12.
50. Notarnicola M, Messa C, Pricci M, Guerra V, Altomare DF, Montemurro S, et al. Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left sided human colon cancer. Anticancer Res 2004;24:3887-42.
51. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008;123:951-7.
52. Malicki S, Winiarski M, Matlok M, Kostarczyk W, Guzdek A, Konturek PC. IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. J Physiol Pharmacol 2009;60:141-6.
53. Bergman M, Salman H, Djaldetti M, Bessler H. Statins as modulators of colon cancer cells induced cytokine secretion by human PBMC. Vascul Pharmacol 2011;54:88-92.
54. Lakshminarayana Reddy CN, Vyjayanti VN, Notani D, Galande S, Kotamraju S. Down-regulation of the global regulator SATB1 by statins in COLO205 colon cancer cell. Mol Med Report 2010;3:857-61.
55. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2008;17:88-94.
56. Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostatespecific antigen expression. J Pharmacol Exp Ther 2011;336:496-505.
57. Yokomizo A, Shiota M, Kashiwagi E, Kuroiwa K, Tatsugami K, Inokuchi J, et al. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells. Prostate 2011;71:298-304.
58. Yang L, Egger M, Plattner R, Klocker H, Eder IE. Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. Urology 2011;77:1508.e1-7.
59. Parikh A, Childress C, Deitrick K, Lin Q, Rukstalis D, Yang W. Statininduced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate 2010;70:971-81.
60. Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, et al. Pathologist Multi Center Study Group. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology 1999;54:467-72.
61. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A meta-analysis of six randomized clinical trials and 13 observational studies. Int J Cancer 2008;123:889-904.
62. Chang CC, Ho SC, Chiu HF, Yang CY. Statins increase the risk of prostate cancer: A population-based case control study. Prostate 2011;71:1818-24.
63. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:2226-32.
64. Park IH, Kim JY, Jung JI, Han JY. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-ras mutations. Invest New Drugs 2010;28:791-9.
65. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, Arcaro A. Potent inhibition of small cell lung cancer cell growth by simvastatin reveals selective functions of ras isoforms in growth factor signaling. Oncogene 2006;25:877-87.
66. Sanli T, Liu C, Rashid A, Hopmans SN, Tsiani E, Schultz C, et al. Lovastatin sensitizes lung cancer cells to ionizing radiation: Modulation of molecular pathways of radiosensitive and tumor suppression. J Thorac Oncol 2011;6:439-50.
67. Hanai JI, Doro N, Sasaki AT, Kobayashi S, Cantley LC, Seth P, et al. Inhibition of lung cancer growth: ATP citrate lyase knockdown and stati treatment leads to dual blockade of mitogen activated protein kinase and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol 2012;227(4):1709-20.
68. Maksimova E, Yie TA, Rom WN. In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent. Lung 2008:186:45-54.
69. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006;118:773-9.
70. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce risk of lung cancer in human: A large case control study of US veterans. Chest 2007;131:1282-8.
71. Han JY, Lim KY, Yu SY, Yun T, Kim HT, Lee JS. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer 2011;117:2178-85.
72. Sutter AP, Maaser K, Höpfner M, Huether A, Schuppan D, Scherübl H. Cell cycle arrest and apoptosis in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005;43:808-16.
73. Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, Lehnert M. Simvastatin inhibits cell growth and induce apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med 2010;26:735-41.
74. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, et al. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 2011;71:2286-97.
75. Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basañez G, et al. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res 2008;68:5246-56.
76. Kim W, Yoon JH, Kim JR, Jang IJ, Bang YJ, Kim YJ, et al. Synergistic antitumor efficacy and protein kinase C-beta inhibitor in hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;64:497-507.
77. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/ MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004;64:6461-8.
78. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005;26:883-91.
79. Infante E, Heasman SJ, Ridley AJ. Statins inhibit T-acute lymphoblastic leukemia cell adhesion and migration through Rap1b. J Leukoc Biol 2011;89:577-86.
80. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004;101:4960-5.
81. Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007;67:4524-32.
82. Van der Weide K, de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. Combining simvastatin with the farnesyltransferase inhibitor tipifarni results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res 2009;15:3076-83.
83. Calabro A, Tai J, Allen SL, Budman DR. In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: Potential implications in acute leukemia. Anticancer Drugs 2008;19:705-12.
84. Lishner M, Bar-Sef A, Elis A, Fabian I. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med 2001;49:319-24.
85. Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5:e64.
86. Sondergaard TE, Pedersen PT, Andersen TL, Søe K, Lund T, Ostergaard B, et al. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol Oncol 2009;27:17-22.
87. Iwata H, Matsuo K, Hara S, Takeuchi K, Aoyama T, Murashige N, et al. Use of hydroxyl-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 2006;97:133-8.
88. Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: Potential therapeutic relevance. BMC Cancer 2010;10:103.
89. Kidera Y, Tsubaki M, Yamazoe Y, Shoji K, Nakamura H, Ogaki M, et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J Exp Clin Cancer Res 2010;29:127.
90. Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol 2008;90:9-17.
91. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 2008;44:2122-32.
92. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: A series of nested case-control studies. BMC Cancer 2011;11:409.
93. Wood M. Statins and breast cancer biomarkers. Vermont Cancer Center at University of Vermont and Fletcher Allen Health Care; United States of America: Clinicaltrial gov NCT00914017.
94. Wolmark N. Statin polyp prevention trial in patients with resected colon cancer. Clinicaltrial gov NCT01011478.
95. Bujanda L. Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer. Department of Gastroenterology at Hospital; Spain: Clinicaltrial gov NCT01038154.
96. Limburg PJ. Randomized phase II trial of atorvastatin, RAFTILOSE® Synergy1, and sulindac among patients at increased risk for sporadic colorectal neoplasia. Mayo Clinic Cancer Center; United States of America: Clinicaltrial gov NCT00335504.
97. Jouve JL, Denis J. Randomized phase III Trial sorafenib-pravastatin versus sorafenib alone for the palliative treatment of Child-Pugh A hepatocellular carcinoma. Hospital Du Bocage; France: Clinicaltrial gov NCT01075555.
98. Seckl MJ. A multicentre phase III randomized double blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small lung cancer. Charing Cross Hospital; England: Clinicaltrial gov NCT00433498.
99. Kang WK. Placebo-controlled, double-blinded phase III trial of XP (Capecitabine/CDDP) simvastatin in advanced gastric cancer patients. Samsung Medical Center; South Korea: Clinicaltrial gov NCT01099085.
100. Park YS, Kim YH. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Samsung Medical Center; South Korea: Clinicaltrial gov NCT00944463.
101. Meyskens FL. A randomized double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center; United States of America: Clinicaltrial gov NCT00462280.